US pharmaceutical innovation in an international context

American Journal of Public Health

Volumn 100, Issue 6, 2010, Pages 1075-1080

  Keyhani, Salomeh ^a,b   Wang, Steven ^c   Hebert, Paul ^d,e   Carpenter, Daniel ^f   Anderson, Gerard ^g  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f HARVARD UNIVERSITY   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

ARTICLE; AUSTRALIA; AUSTRIA; COMPARATIVE STUDY; CZECHOSLOVAKIA; DENMARK; DRUG COST; DRUG INDUSTRY; ECONOMICS; FINANCIAL MANAGEMENT; HUMAN; KOREA; NORWAY; SPAIN; STATISTICS; UNITED STATES;

AUSTRALIA; AUSTRIA; CZECHOSLOVAKIA; DENMARK; DRUG COSTS; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; ECONOMICS; HUMANS; KOREA; NORWAY; RESEARCH SUPPORT AS TOPIC; SPAIN; UNITED STATES;

EID: 77952282664     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2009.178491     Document Type: Article

References (27)

1. Kyle M. Pharmaceutical price controls and entry strategy. Rev Econ Stat. 2007;89(1):88-99.
2. Foreign Government Pharmaceutical Price and Access Controls. Washington, DC: Phamiaceutical Research and Manufacturers of America (prepared for the Dept of (commerce); 2004.
3. Hopkins Tanne J. FDA chief wants other rich countries to share drug development costs. BMJ. 2003; 327{7419):830.
4. HIRMA. Statement regarding benefits of US innovation [news release]. Available at: http://www.phrma.org/ new-room/press-releases/phrma-statment- regarding-benefits-of-u.s.- innovation. Accessed September 7, 2009.
5. International Trade and Pharmaceuticals. Subcommittee on Health Care and Subcommittee on International Trade, Committee on Finance, United States Senate April 27, 2004(testimony of William K. Hubbard, Associate Commissioner for Policy and Planning, Food and Drag Administration). Washington, DC: US Department of Health and Human Services; 2004.
6. Anderson GF, Shea DG, Hussey PS, Keyhani S, Zephyrin L. Doughnut holes and price controls. Health Aff (Millwood}. 2004:(suppl web exclusives):W4-39- 404.
7. Iglehart JK. The new Medicare prescription-drug benefit-a pure power play. N Engl J Med 2004;350(8): 826-833.
8. Gottlieb S. How Obama would stifle drug innovation. Wall Street Journal. October 18, 2008.
9. Henry D, Lexchin J. The pharmaceutical industry as a medianes provider. Lancet 2002;360(9345):1590-1595.
10. Soumerai SB, Pierre-Jacques M, Zhang F, et al. Costrelated medication nonadherenee among elderly and disabled Medicare beneficiaries: a national survey 1 year before the Medicare drug benefit. Arch Intern Med 2006:166(17):1829-1835.
11. light DW, Lexchin J. Foreign free riders and the highprice of US medicines. BMJ. 2005:331(7522):958-960.
12. Electronic Orange Book. Washington, DC: Food and Drug Administration; July 2008. Available at: http:// www.accessdata.fda.gov/scripts/cder/ob/default. cfm. Accessed May 17, 2008.
13. Barton JH, Emanuel EJ. The patents-based pharmaceutical development process: rationale, problems, and potential reforms. JAMA. 2005;294(16):2075- 2082.
14. EDGAR Company Search. Available at http://www.sec.gov/edgar/searchedgar/ companysearch.html Accessed March 20, 2009.
15. Peterson CL, Burton R. In: Service CR, ed. CRS Report for Congress: US Health Care Spending: Comparison with other OECD Countries. Washington, DC: US Congress; 2007. Available at http://assets.opencrs.com/ rpts/RL34175-20070917. pdf. Accessed October 20, 2009.
16. Maynard A, Bloor K. Dilemmas in regulation of the market for pharmaceuticals. Health Aff (Millwood). 2003; 22(3):31-41.
17. Sax P. Spending on medicines in Israel in an international context Isr Med Assoc J. 2005;7(5):286-291.
18. International Macroeconomic Dataset. United States Department of Agriculture Washington, DC: Economic Research Service; 2008.
19. Reinhardt UE, Hussey PS, Anderson GFUS. Health care spending in an international context Health Aff (Millwood). 2004;23{3):10-25.
20. Danzon PM Ketcham JD. Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand. Front Health Policy Res. 2004;7:1-54.
21. López GP. Review of the Literature on Reference Pricing. Barcelona, Spain: Department of Economics and Business, Universitat Pompeu Fahra; 1999. Working Papers, Research Center on Health and Economics no. 362. Available at: http://ideas.repec.org/p/upf/upfses/ 362.html. Accessed October 17, 2009.
22. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics. 2003; 21(2):89-103.
23. 23. Bloor K, Maynard A, Freemantie N. Lessons from international experience in controlling pharmaceutical expenditure III: regulating industry. BMJ. 1996; 313(7048):33-35. (Pubitemid 26229888)
24. Aaserud M, Dahlgren AT, Kostens JP, Oxman AD, Ramsay C, Sturm H. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst Rev. 2006; (2):CD005979.
25. Vernon JA. Examining the link between price regulation and pharmaceutical R&D investment. Health Econ. 2005;14(1):1-16.
26. Profitability Among Pharmaceutical Manufecturers Compared to Other Industries. 1995-2004, In: Trends and Indicators in the Changing Health Care Marketplace. The Kaiser Family Foundation. Available at http:// www.kff.org/insurance/7031/ti2004-1-21.cfm. Accessed June 20, 2009.
27. A Comparison of Pharmaceutical Research and Development Spending in Canada and Sehet Countries. Patented Medicine Prices Review Board; December 2002. PMPRB Study Series S-0217. Available at: http:// www.pmprb-cepmb.gc.ca/ CMFiles/ss-0217e14HCB492003-5262.pdf. Accessed September 7, 2009.